Faced with a dramatic slowdown in sales in mature pharmaceutical markets, multinational pharmaceutical companies
are looking to substantially increase their sales in India and other emerging markets. The Indian market
is growing by more than 10% per year, but foreign companies will need to overcome signifi cant obstacles to
succeed in a market currently dominated by domestic manufacturers.
Questions Answered in This Report
The Indian population is forecast to grow from its present size of 1.2 billion to 1.7 billion in 2050. How will
the age breakdown of the population evolve over time? How will the balance between India’s urban and
rural populations change in the coming years?
Only a minority of Indians have health insurance. What are the main forms of health insurance? How do
most Indians fund healthcare and medications?
The Indian government controls the prices of 74 scheduled medicines. Which agents are subject to price
control? How are prices of other drugs regulated? How does the government penalize overcharging
for drugs? How do prices in India compare with prices in other markets? What pricing reforms is the
Indian government contemplating?
Scope
Demographic trends: population breakdown by age and sex; population breakdown by geographic distribution.
Organization and funding of healthcare: overview of the Indian healthcare system; access to healthcare; health insurance; out-of-pocket expenditures.
Pharmaceutical pricing: historical price controls; current price control system; price adjustments;
penalties for overcharging for drugs; international price comparison; multinational companies’ pricing strategies.
Outlook and implications for the pharmaceutical industry: encouraging commercial outlook;potential government reforms; opportunities and threats for multinationals.
(0 items)
